ReviewSignal transduction and targeted therapy2021
Myeloid cells in COVID-19 microenvironment.
Review in Signal transduction and targeted therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 29 citations in OpenAlex.
- Caspase-11-mediated hyperinflammation impairs CD8+ T cell immunity and viral clearance in severe SARS-CoV-2 infection.JCI insight · 2026Article
- Article
- CD169Frontiers in cellular and infection microbiology · 2026Article
- Pulmonary Myeloid Cells in Mild Cases of COVID-19 Upregulate the Intracellular Fc ReceptorInternational journal of molecular sciences · 2025Article
- Increased levels of GM-CSF and CXCL10 and low CD8Immunity & ageing : I & A · 2024Article
- Cell-free DNA methylation reveals cell-specific tissue injury and correlates with disease severity and patient outcomes in COVID-19.Clinical epigenetics · 2024Article
- Mechanisms of endothelial activation, hypercoagulation and thrombosis in COVID-19: a link with diabetes mellitus.Cardiovascular diabetology · 2024Review
- Two new and effective food-extracted immunomodulatory agents exhibit anti-inflammatory response activity in the hACE2 acute lung injury murine model of COVID-19.Frontiers in immunology · 2024Article
- Persistence of circulating CD169+monocytes and HLA-DR downregulation underline the immune response impairment in PASC individuals: the potential contribution of different COVID-19 pandemic waves.Current research in microbial sciences · 2024Article
- Integrating transcriptomics, eQTL, and Mendelian randomization to dissect monocyte roles in severe COVID-19 and gout flare.Frontiers in genetics · 2024Article
- Immunologic and inflammatory consequences of SARS-CoV-2 infection and its implications in renal disease.Frontiers in immunology · 2024Review
- Differential Transcriptomic Landscapes of SARS-CoV-2 Variants in Multiple Organs from Infected Rhesus Macaques.Genomics, proteomics & bioinformatics · 2023Article
- Identification of Gene Markers Associated with COVID-19 Severity and Recovery in Different Immune Cell Subtypes.Biology · 2023Article
- Reconstruction of the cell pseudo-space from single-cell RNA sequencing data with scSpace.Nature communications · 2023Article
- The kinetics of chemokine autoantibodies in COVID-19.Nature immunology · 2023Article
- Targeted plasma proteomics reveals signatures discriminating COVID-19 from sepsis with pneumonia.Respiratory research · 2023Article
- Neutrophil heterogeneity and aging: implications for COVID-19 and wound healing.Frontiers in immunology · 2023Review
- Innate immunity, cytokine storm, and inflammatory cell death in COVID-19.Journal of translational medicine · 2022Review
- α2,6-Sialylation is Upregulated in Severe COVID-19 Implicating the Complement Cascade.medRxiv : the preprint server for health sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Varying differentiation of myeloid cells is common in tumors, inflammation, autoimmune diseases, and metabolic diseases. The release of cytokines from myeloid cells is an important driving factor that leads to severe COVID-19 cases and subsequent death. This review briefly summarizes the results of single-cell sequencing of peripheral blood, lung tissue, and cerebrospinal fluid of COVID-19 patients and describes the differentiation trajectory of myeloid cells in patients. Moreover, we describe the function and mechanism of abnormal differentiation of myeloid cells to promote disease progression. Targeting myeloid cell-derived cytokines or checkpoints is essential in developing a combined therapeutic strategy for patients with severe COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.